Mesoblast Plans New GvHD Trial After Another FDA Rejection

Mesoblast plans to conduct a new trial for evaluating the efficacy of remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (GvHD), after receiving yet another request for more data.